Intranasal Oxytocin Trial Investigates Efficacy in Reducing Alcohol Withdrawal and Long-Term Drinking in Alcohol Dependence

Alcohol dependence (alcohol addiction) is a chronic, relapsing brain disease affecting millions globally, characterized by compulsive alcohol seeking and use despite harmful consequences. A critical challenge is managing alcohol withdrawal syndrome (AWS), which can range from mild tremors to severe, life-threatening seizures and delirium, often necessitating supervised medical detoxification. Current pharmacotherapies for AWS primarily focus on symptom management and have limited efficacy in preventing long-term relapse. This leaves a significant gap for interventions that can address both acute withdrawal and the underlying neurobiological drivers of craving and relapse. Oxytocin, a hypothalamic neuropeptide, is known for its roles in social bonding and stress regulation. Emerging research suggests it modulates brain reward systems, particularly the dopaminergic mesolimbic pathway, and influences stress-related circuits like the hypothalamic-pituitary-adrenal (HPA) axis, both implicated in the development and maintenance of alcohol dependence. This trial investigates oxytocin's potential to modulate these pathways, aiming to reduce withdrawal severity and decrease subsequent alcohol consumption.

This Phase 3, prospective, randomized, parallel-group, placebo-controlled clinical trial (NCT02903251) recruited individuals diagnosed with alcohol dependence who were admitted for medical detoxification. Participants were randomized to receive either intranasal oxytocin or a placebo nasal spray. The study hypothesized that intranasal oxytocin treatment would significantly decrease the severity of alcohol withdrawal symptoms during detoxification. Furthermore, it aimed to assess if 12 weeks of intranasal oxytocin treatment in an outpatient setting would lead to a sustained decrease in drinking behavior. Primary endpoints likely included validated scales for withdrawal severity (e.g., CIWA-Ar) and measures of alcohol consumption (e.g., drinks per day, abstinence rates). A long-term follow-up component also planned to evaluate the sustained effects of oxytocin on alcohol dependence at 60 days and 1 year post-treatment.